These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26699176)

  • 1. Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.
    Baerlocher GM; Burington B; Snyder DS
    N Engl J Med; 2015 Dec; 373(26):2580. PubMed ID: 26699176
    [No Abstract]   [Full Text] [Related]  

  • 2. Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.
    Tefferi A
    N Engl J Med; 2015 Dec; 373(26):2580-1. PubMed ID: 26709404
    [No Abstract]   [Full Text] [Related]  

  • 3. Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.
    Bjørn ME; Nielsen CH; Hasselbalch HC
    N Engl J Med; 2015 Dec; 373(26):2579-80. PubMed ID: 26699178
    [No Abstract]   [Full Text] [Related]  

  • 4. Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.
    El Fassi D
    N Engl J Med; 2015 Dec; 373(26):2579. PubMed ID: 26699177
    [No Abstract]   [Full Text] [Related]  

  • 5. Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
    Baerlocher GM; Oppliger Leibundgut E; Ottmann OG; Spitzer G; Odenike O; McDevitt MA; Röth A; Daskalakis M; Burington B; Stuart M; Snyder DS
    N Engl J Med; 2015 Sep; 373(10):920-8. PubMed ID: 26332546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating Myeloproliferation--On Target or Off?
    Armanios M; Greider CW
    N Engl J Med; 2015 Sep; 373(10):965-6. PubMed ID: 26332552
    [No Abstract]   [Full Text] [Related]  

  • 7. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
    Tefferi A; Lasho TL; Begna KH; Patnaik MM; Zblewski DL; Finke CM; Laborde RR; Wassie E; Schimek L; Hanson CA; Gangat N; Wang X; Pardanani A
    N Engl J Med; 2015 Sep; 373(10):908-19. PubMed ID: 26332545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
    Wu X; Smavadati S; Nordfjäll K; Karlsson K; Qvarnström F; Simonsson M; Bergqvist M; Gryaznov S; Ekman S; Paulsson-Karlsson Y
    Biochim Biophys Acta; 2012 Dec; 1823(12):2130-5. PubMed ID: 22906540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.
    Mosoyan G; Kraus T; Ye F; Eng K; Crispino JD; Hoffman R; Iancu-Rubin C
    Leukemia; 2017 Nov; 31(11):2458-2467. PubMed ID: 28270692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.
    Salloum R; Hummel TR; Kumar SS; Dorris K; Li S; Lin T; Daryani VM; Stewart CF; Miles L; Poussaint TY; Stevenson C; Goldman S; Dhall G; Packer R; Fisher P; Pollack IF; Fouladi M; Boyett J; Drissi R
    J Neurooncol; 2016 Sep; 129(3):443-451. PubMed ID: 27350411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma.
    Ferrandon S; Malleval C; El Hamdani B; Battiston-Montagne P; Bolbos R; Langlois JB; Manas P; Gryaznov SM; Alphonse G; Honnorat J; Rodriguez-Lafrasse C; Poncet D
    Mol Cancer; 2015 Jul; 14():134. PubMed ID: 26183089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).
    Mascarenhas J; Sandy L; Lu M; Yoon J; Petersen B; Zhang D; Ye F; Newsom C; Najfeld V; Hochman T; Goldberg JD; Hoffman R
    Leuk Res; 2017 Feb; 53():13-19. PubMed ID: 27930945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase inhibitors: a patent review (2010-2015).
    Man RJ; Chen LW; Zhu HL
    Expert Opin Ther Pat; 2016 Jun; 26(6):679-88. PubMed ID: 27104627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial watch: Telomerase inhibitor shows promise in myeloproliferative disorders.
    Cully M
    Nat Rev Drug Discov; 2015 Nov; 14(11):741. PubMed ID: 26514857
    [No Abstract]   [Full Text] [Related]  

  • 16. The effects of telomerase inhibition on prostate tumor-initiating cells.
    Marian CO; Wright WE; Shay JW
    Int J Cancer; 2010 Jul; 127(2):321-31. PubMed ID: 19908230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No end in sight for telomerase-targeted cancer drugs.
    Williams SC
    Nat Med; 2013 Jan; 19(1):6. PubMed ID: 23295993
    [No Abstract]   [Full Text] [Related]  

  • 18. Imetelstat (GRN163L)--telomerase-based cancer therapy.
    Röth A; Harley CB; Baerlocher GM
    Recent Results Cancer Res; 2010; 184():221-34. PubMed ID: 20072842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase inhibitors for the treatment of brain tumors and the potential of intranasal delivery.
    Hashizume R; Gupta N
    Curr Opin Mol Ther; 2010 Apr; 12(2):168-75. PubMed ID: 20373260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.